Aduro Biotech (ADRO) Reports First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD
Tweet Send to a Friend
Aduro Biotech, Inc. (NASDAQ: ADRO) announced today that the first patient has been dosed in the Phase 1 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
